Johnson & Johnson : First Quarter 2026 1Q26 Other Financial Disclosures

Published: 2026-04-14 06:26:17 ET JNJ

Published on 04/14/2026 at 06:26 am EDT

First Quarter 2026

Other Financial Disclosures

Table of Contents

Table 1: Sales by Segment

Table 2: Sales by Geographic Area

Table 3: Sales of Key Products/Franchises

Table 4: Condensed Consolidated Statement of Earnings - QTD

Table 5: Non-GAAP Adjusted Operational Sales Growth - QTD

Table 6: Non-GAAP Adjusted Net Earnings

Table 7: Non-GAAP P&L by Segment Reconciliation 2026 - QTD

Table 8: Non-GAAP P&L by Segment Reconciliation 2025 - QTD

3 - 7

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

FIRST QUARTER

Percent Change

2026

2025

Total

Operations

Currency

Sales to customers by

segment of business

Innovative Medicine

U.S.

$ 8,871

8,092

9.6

International

6,555

5,781

13.4

4.3

9.1

15,426

13,873

11.2

7.4

3.8

MedTech

U.S.

4,459

4,213

5.9

International

4,177

3,807

9.7

3.2

6.5

8,636

8,020

7.7

4.6

3.1

U.S.

13,330

12,305

8.3

International

10,732

9,588

11.9

3.9

8.0

Worldwide

$ 24,062

21,893

9.9

6.4

3.5

(Unaudited; Dollars in Millions)

FIRST QUARTER

Percent Change

2026

2025

Total

Operations

Currency

Sales to customers by

geographic area

U.S.

$ 13,330 12,305 8.3 % 8.3 -

Europe

5,848

5,110

14.5

2.7

11.8

Western Hemisphere excluding U.S.

1,293

1,167

10.8

2.5

8.3

Asia-Pacific, Africa

3,591

3,311

8.5

6.1

2.4

International

10,732

9,588

11.9

3.9

8.0

Worldwide

$ 24,062 21,893 9.9 % 6.4 3.5

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

FIRST QUARTER

% Change

2026

2025

Reported

Operational (1)

Currency

$ 3,615

3,013

20.0%

3,358

2,664

26.0%

15.3%

10.7%

6,973

5,678

22.8%

17.8%

5.0%

2,208

1,829

20.7%

1,756

1,409

24.7%

14.0%

10.7%

3,964

3,237

22.5%

17.8%

4.7%

433

318

36.2%

164

597

369

62.1%

57.4%

4.7%

127

105

20.6%

63.1%

52.1%

11.0%

202

151

33.5%

30.1%

3.4%

101

48.5%

152

76.7%

72.8%

3.9%

175

113

55.1%

257

141

82.7%

80.5%

2.2%

342

292

17.3%

607

479

26.7%

15.5%

11.2%

949

771

23.1%

16.2%

6.9%

143

235

(39.1)%

517

474

9.1%

(1.4)%

10.5%

660

709

(6.9)%

(13.9)%

7.0%

58.8%

106

160

(33.9)%

(36.3)%

2.4%

192

214

(10.6)%

(12.5)%

1.9%

INNOVATIVE MEDICINE SEGMENT (2)

Intl WW

DARZALEX US

Intl WW

CARVYKTI US

Intl WW

TECVAYLI US

Intl WW

TALVEY US

Intl WW

RYBREVANT / LAZCLUZE US

Intl WW

ERLEADA US

Intl WW

IMBRUVICA US

Intl WW

OTHER ONCOLOGY (3)

Intl WW

See footnotes at end of schedule

FIRST QUARTER

2026

$ 1,855

1,524

3,380

1,042

566

1,608

269

378

647

269

136

422

220

435

656

1,494

681

2,175

406

468

270

-270

758

280

1,038

115

136

224

262

2025

2,196

1,510

% Change

Reported Operational (1) Currency

(15.5)% (15.5)% -

0.9% (6.4)% 7.3%

(8.8)% (11.8)% 3.0%

73.9% 73.9% -

58.9% 46.8% 12.1%

68.3% 63.8% 4.5%

(7.8)% (7.8)% -

3.0% (4.1)% 7.1%

(1.7)% (5.7)% 4.0%

(14.4)% (14.4)% -

78.6% 78.6% -

(4.8)% (10.5)% 5.7%

(9.5)% (11.2)% 1.7%

(77.6)% (77.6)% -

(32.4)% (37.7)% 5.3%

(59.7)% (61.7)% 2.0%

* * -

* * *

54.3% 54.3% -

0.3% (6.3)% 6.6%

32.0% 29.3% 2.7%

47.0% 47.0% -

42.4% 28.7% 13.7%

46.4% 44.5% 1.9%

* * -

- - -

* * -

21.2% 21.2% -

1.1% (4.9)% 6.0%

15.0% 13.2% 1.8%

(43.4)% (43.4)% -

4.3% (0.6)% 4.9%

(8.0)% (11.7)% 3.7%

32.6% 32.6% -

(9.7)% (16.3)% 6.6%

(5.4)% (11.3)% 5.9%

3,707

599

356

956

292

366

659

314

143

467

981

644

1,625

968

679

1,647

276

320

625

277

903

110

148

248

277

Intl WW

TREMFYA US

Intl WW

SIMPONI / SIMPONI ARIA US

Intl WW

REMICADE

US Exports (4)

Intl WW

STELARA US

Intl WW

OTHER IMMUNOLOGY US

Intl WW

SPRAVATO US

Intl WW

CAPLYTA (5)

Intl WW

INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA

Intl WW

CONCERTA / Methylphenidate US

Intl WW

OTHER NEUROSCIENCE US

Intl WW

See footnotes at end of schedule

FIRST QUARTER

2026

$ 831

304

1,135

385

483

433

172

606

342

547

889

402

409

334

109

443

734

142

876

642

-642

142

233

1,907

993

2,899

8,871

6,555

$ 15,426

2025

744

281

% Change

Reported Operational (1) Currency

11.7% 11.7% -

8.2% 1.0% 7.2%

10.7% 8.7% 2.0%

5.4% 5.4% -

14.3% 5.1% 9.2%

7.1% 5.4% 1.7%

19.3% 19.3% -

8.7% 1.7% 7.0%

16.1% 14.0% 2.1%

(21.1)% (21.1)% -

(8.3)% (11.8)% 3.5%

(12.1)% (14.5)% 2.4%

8.6% 8.6% -

12.2% 1.3% 10.9%

10.8% 4.1% 6.7%

(13.1)% (13.1)% -

14.8% 3.2% 11.6%

14.1% 2.8% 11.3%

9.5% 9.5% -

11.2% 0.7% 10.5%

10.0% 7.4% 2.6%

(56.9)% (56.9)% -

(8.3)% (14.7)% 6.4%

(10.4)% (16.5)% 6.1%

(14.2)% (14.2)% -

(10.4)% (17.5)% 7.1%

(13.6)% (14.7)% 1.1%

(7.0)% (7.0)% -

- - -

(7.0)% (7.0)% -

(44.5)% (44.5)% -

(10.4)% (17.5)% 7.1%

(27.8)% (31.2)% 3.4%

(0.4)% (0.4)% -

7.1% (2.0)% 9.1%

2.1% (0.9)% 3.0%

9.6% 9.6% -

13.4% 4.3% 9.1%

11.2% 7.4% 3.8%

1,025

365

451

363

159

522

315

487

802

350

358

305

403

855

158

1,013

690

165

158

323

1,914

926

2,840

8,092

5,781

13,873

Intl WW

UPTRAVI US

Intl WW

OPSUMIT / OPSYNVI US

Intl

OTHER PULMONARY HYPERTENSION US

Intl WW

EDURANT / rilpivirine US

Intl WW

PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US

Intl WW

OTHER INFECTIOUS DISEASES US

Intl WW

XARELTO US

Intl WW

OTHER US

Intl WW

TOTAL INNOVATIVE MEDICINE US

Intl

See footnotes at end of schedule

FIRST QUARTER

2026

1,399

978

2,377

736

753

1,489

389

100

488

242

305

1,046

1,465

2,511

477

646

1,123

569

819

1,388

2025

1,261

842

% Change

Reported Operational (1) Currency

10.9% 10.9% -

16.1% 9.9% 6.2%

13.0% 10.5% 2.5%

7.6% 7.6% -

18.0% 11.7% 6.3%

12.6% 9.5% 3.1%

14.5% 14.5% -

23.5% 13.9% 9.6%

16.3% 14.4% 1.9%

17.8% 17.8% -

21.3% 19.3% 2.0%

18.5% 18.1% 0.4%

0.7% 0.7% -

(13.4)% (17.5)% 4.1%

(9.1)% (11.9)% 2.8%

4.4% 4.4% -

5.1% (1.1)% 6.2%

4.8% 1.2% 3.6%

4.2% 4.2% -

4.9% (1.0)% 5.9%

4.6% 1.2% 3.4%

4.5% 4.5% -

5.2% (1.3)% 6.5%

4.9% 1.1% 3.8%

2,103

684

638

1,323

339

420

206

258

103

1,002

1,394

2,396

457

616

1,073

544

778

1,323

MEDTECH SEGMENT (2)

Intl WW

ELECTROPHYSIOLOGY US

Intl WW

ABIOMED US

Intl WW

SHOCKWAVE US

Intl WW

OTHER CARDIOVASCULAR US

Intl WW

ADVANCED US

Intl WW

GENERAL US

Intl WW

See footnotes at end of schedule

VISION

Intl

CONTACT LENSES / OTHER

Intl

SURGICAL

Intl

ORTHOPAEDICS

Intl

HIPS

Intl

KNEES

Intl

TRAUMA

Intl

SPINE, SPORTS & OTHER

Intl

TOTAL MEDTECH

Intl

FIRST QUARTER

2026

579

2025

566

% Change

Reported

Operational (1)

Currency

2.4%

785

713

10.1%

4.6%

5.5%

1,365

1,279

6.7%

3.6%

3.1%

468

452

3.7%

501

467

7.2%

1.7%

5.5%

969

919

5.5%

2.7%

2.8%

111

114

(2.9)%

285

246

15.6%

10.1%

5.5%

396

361

9.7%

6.0%

3.7%

1,435

1,384

3.7%

948

857

10.6%

2.4%

8.2%

2,383

2,241

6.3%

3.2%

3.1%

277

263

5.2%

159

146

8.9%

0.3%

8.6%

436

409

6.5%

3.5%

3.0%

239

231

3.3%

181

158

14.6%

6.5%

8.1%

420

389

7.9%

4.6%

3.3%

532

502

6.1%

301

270

11.4%

3.1%

8.3%

833

772

8.0%

5.0%

3.0%

387

388

(0.1)%

307

283

8.4%

0.7%

7.7%

694

671

3.5%

0.2%

3.3%

4,459

4,213

5.9%

4,177

3,807

9.7%

3.2%

6.5%

$ 8,636

8,020

7.7%

4.6%

3.1%

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely

* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Includes the sales of ZYTIGA which were previously disclosed separately

(4) Reported as U.S. sales

(5) Acquired with Intra-Cellular Therapies on April 2, 2025

(Unaudited; in Millions Except Per Share Figures)

FIRST QUARTER

2026 2025 Percent

Percent Percent Increase

Amount

to Sales Amount to Sales (Decrease)

Sales to customers $ 24,062

100.0 $ 21,893 100.0 9.9

Cost of products sold 8,106

33.7 7,357 33.6 10.2

Gross Profit 15,956

66.3 14,536 66.4 9.8

Selling, marketing and administrative expenses 6,034

25.1 5,112 23.3 18.0

Research and development expense 3,527

14.7 3,225 14.7 9.4

In-process research and development impairments 36

0.1 - -

Interest (income) expense, net 43

0.2 (128) (0.6)

Other (income) expense, net 294

1.2 (7,321) (33.4)

Restructuring 32

0.1 17 0.1

Earnings before provision for taxes on income 5,990

24.9 13,631 62.3 (56.1)

Provision for taxes on income 755

3.1 2,632 12.1 (71.3)

Net earnings $ 5,235

21.8 $ 10,999 50.2 (52.4)

Net earnings per share (Diluted)

$ 2.14

Average shares outstanding (Diluted)

2,445.2

Effective tax rate

12.6

19.3

Adjusted earnings before provision for taxes and net earnings (1)

Earnings before provision for taxes on income

$ 7,821

32.5

$ 8,011

36.6

(2.4)

Net earnings

$ 6,614

27.5

$ 6,706

30.6

(1.4)

Net earnings per share (Diluted)

$ 2.70

$ 2.77

(2.5)

Effective tax rate

15.4

16.3 %

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries

Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth

FIRST QUARTER 2026 ACTUAL vs. 2025 ACTUAL

WW As Reported

11.2%

7.7%

9.9%

U.S.

9.6%

5.9%

8.3%

International

13.4%

9.7%

11.9%

WW Currency

U.S.

International

3.8

9.1

3.1

6.5

3.5

8.0

WW Operational

7.4%

4.6%

6.4%

U.S.

9.6%

5.9%

8.3%

International

4.3%

3.2%

3.9%

Caplyta

U.S.

International

(1.9)

(3.3)

0.0

(1.2)

(2.2)

0.0

All Other Acquisitions and Divestitures (A&D)

U.S.

International

0.1

0.0

0.2

0.1

0.2

0.0

0.1

WW Adjusted Operational Ex A&D

5.6%

4.7%

5.3%

U.S.

6.3%

6.1%

6.2%

International

4.5%

3.2%

4.0%

Johnson & Johnson and Subsidiaries

Reconciliation of Non-GAAP Financial Measures

(Dollars in Millions Except Per Share Data) 2026 2025

Net Earnings, after tax- as reported $5,235 $10,999

Pre-tax Adjustments

Intangible Asset Amortization expense

Litigation related

Orthopaedics Separation related

Acquisition, integration and divestiture related

Restructuring related 1

IPR&D impairments

(Gains)/losses on securities

1,247

330

119

(59)

1,120

(6,966)

132

Tax Adjustments

Tax impact on special item adjustments 2

Tax legislation and other tax related

Adjusted Net Earnings, after tax

Average shares outstanding (Diluted)

Adjusted net earnings per share (Diluted)

Operational adjusted net earnings per share (Diluted)

(424)

(28)

$6,614

2,445.2

$2.70

$2.57

1,315

$6,706

2,423.8

$2.77

1 In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of $7 million in the fiscal first quarter of 2026 and $55 million in the fiscal first quarter of 2025 primarily includes costs related to market and product exits. This program was substantially completed in Q4 2025.

In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. The restructuring expense of $55 million in the fiscal first quarter of 2026 primarily includes costs related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026.

The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving

at adjusted earnings.

Johnson & Johnson and Subsidiaries

GAAP to Non-GAAP Reconciliation

$ in Millions

Year to Date

Innovative Medicine

First Quarter Mar. 29, 2026

GAAP

Intangible asset

amortization

Litigation related

In-process

research and development

impairments

Restructuring related

Acquisition, integration

and divestiture related

(Loss)/gain on

securities

Orthopaedics

Separation Related

Tax legislation and other tax

First Quarter Mar. 29, 2026

Non-GAAP

Cost of products sold

$ 4,390

(763)

(10)

$ 3,617

Selling, marketing and admin expenses

2,918

Research and development expense

2,813

Other segment items

(12)

(40)

(46)

(43)

Adjusted Income Before Tax by Segment

5,317

763

(55)

6,121

In-process

MedTech

First Quarter research and Tax legislation First Quarter

Mar. 29, 2026 Intangible asset development Restructuring Acquisition, integration (Loss)/gain on Orthopaedics and other tax Mar. 29, 2026

GAAP amortization Litigation related impairments related and divestiture related securities Separation Related related Non-GAAP

Cost of products sold

$ 3,701

(484)

(25)

$ 3,192

Selling, marketing and admin expenses

2,906

Research and development expense

714

Other segment items

(36)

(37)

(27)

(119)

(98)

Adjusted Income Before Tax by Segment

1,239

484

(41)

(4)

119

1,922

In-process

Expenses not allocated to segments

First Quarter research and Tax legislation First Quarter

Mar. 29, 2026 Intangible asset development Restructuring Acquisition, integration (Loss)/gain on Orthopaedics and other tax Mar. 29, 2026

GAAP amortization Litigation related impairments related and divestiture related securities Separation Related related Non-GAAP

Cost of products sold

$ 15

Selling, marketing and admin expenses

210

Research and development expense

Other segment items

341

(331)

(13)

(3)

Adjusted Income Before Tax by Segment

(566)

331

(222)

In-process

Johnson & Johnson Consolidated

First Quarter research and Tax legislation First Quarter

Mar. 29, 2026 Intangible asset development Restructuring Acquisition, integration (Loss)/gain on Orthopaedics and other tax Mar. 29, 2026

GAAP amortization Litigation related impairments related and divestiture related securities Separation Related related Non-GAAP

Cost of products sold

$ 8,106

(1,247)

(25)

(10)

$ 6,824

Selling, marketing and admin expenses

6,034

Research and development expense

3,527

Other (Income) / Expense

294

(330)

(5)

(86)

(119)

(187)

In-process research and development impairments

(36)

Interest (Income)/Expense

Restructuring

(32)

Adjusted Income Before Tax

5,990

1,247

330

(59)

119

7,821

Provision for taxes on income

755

240

(13)

1,207

Net Earnings

$ 5,235

1,007

258

(8)

(46)

(28)

6,614

Johnson & Johnson and Subsidiaries

GAAP to Non-GAAP Reconciliation

$ in Million

Year to Date

Innovative Medicine

First Quarter March 30, 2025 GAAP

Intangible asset amortization

Litigation related

Restructuring related

Acquisition, integration and divestiture related

(Loss)/gain on securities

Tax legislation and other tax related

First Quarter March 30, 2025 Non-GAAP

Cost of products sold

$ 4,020

(649)

3,371

Selling, marketing and admin expenses

2,261

Research and development expense

2,548

Other segment items

(166)

(20)

(18)

(204)

Adjusted Income Before Tax by Segment

5,210

649

5,897

MedTech

First Quarter

March 30, 2025 GAAP

Intangible asset amortization

Litigation related

Restructuring related

Acquisition, integration and divestiture related

(Loss)/gain on securities

Tax legislation

and other tax related

First Quarter

March 30, 2025 Non-GAAP

Cost of products sold

$ 3,326

(471)

(8)

(52)

2,795

Selling, marketing and admin expenses

2,656

Research and development expense

677

(6)

671

Other segment items

(60)

(47)

(54)

(21)

(182)

Adjusted Income Before Tax by Segment

1,421

471

112

2,080

Expenses not allocated to segments

First Quarter

March 30, 2025 GAAP

Intangible asset amortization

Litigation related

Restructuring related

Acquisition, integration and divestiture related

(Loss)/gain on securities

Tax legislation

and other tax related

First Quarter

March 30, 2025 Non-GAAP

Cost of products sold

$ 11

Selling, marketing and admin expenses

195

Research and development expense

Other segment items

(7,206)

6,966

(240)

Adjusted Income Before Tax by Segment

7,000

(6,966)

Johnson & Johnson Consolidated

First Quarter

March 30, 2025 GAAP

Intangible asset amortization

Litigation related

Restructuring related

Acquisition, integration and divestiture related

(Loss)/gain on securities

Tax legislation

and other tax related

First Quarter

March 30, 2025 Non-GAAP

Cost of products sold

$ 7,357

(1,120)

(8)

(52)

6,177

Selling, marketing and admin expenses

5,112

Research and development expense

3,225

(6)

3,219

Other (Income) / Expense

(7,321)

6,966

(30)

(74)

(39)

(498)

In-process research and development impairments

Interest (Income)/Expense

(128)

Restructuring

(17)

Adjusted Income Before Tax

13,631

1,120

(6,966)

132

8,011

Provision for taxes on income

2,632

188

(1,553)

(12)

1,305

Net Earnings

10,999

932

(5,413)

102

6,706

Disclaimer

Johnson & Johnson published this content on April 14, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 14, 2026 at 10:25 UTC.